18612226

Source:http://linkedlifedata.com/resource/pubmed/id/18612226

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0030705, umls-concept:C0796392, umls-concept:C1527144
pubmed:issue	2
pubmed:dateCreated	2008-7-9
pubmed:abstractText	To evaluate the efficacy and safety of intravitreal bevacizumab for polypoidal choroidal vasculopathy (PCV).
pubmed:commentsCorrections	http://linkedlifedata.com/resource/pubmed/commentcorrection/18612226-10448746, http://linkedlifedata.com/resource/pubmed/commentcorrection/18612226-10458169, http://linkedlifedata.com/resource/pubmed/commentcorrection/18612226-10565519, http://linkedlifedata.com/resource/pubmed/commentcorrection/18612226-11045343, http://linkedlifedata.com/resource/pubmed/commentcorrection/18612226-11131419, http://linkedlifedata.com/resource/pubmed/commentcorrection/18612226-11470706, http://linkedlifedata.com/resource/pubmed/commentcorrection/18612226-11864892, http://linkedlifedata.com/resource/pubmed/commentcorrection/18612226-11992861, http://linkedlifedata.com/resource/pubmed/commentcorrection/18612226-12441716, http://linkedlifedata.com/resource/pubmed/commentcorrection/18612226-12842207, http://linkedlifedata.com/resource/pubmed/commentcorrection/18612226-14557174, http://linkedlifedata.com/resource/pubmed/commentcorrection/18612226-14711438, http://linkedlifedata.com/resource/pubmed/commentcorrection/18612226-15103216, http://linkedlifedata.com/resource/pubmed/commentcorrection/18612226-15148217, http://linkedlifedata.com/resource/pubmed/commentcorrection/18612226-15288991, http://linkedlifedata.com/resource/pubmed/commentcorrection/18612226-15864616, http://linkedlifedata.com/resource/pubmed/commentcorrection/18612226-16156152, http://linkedlifedata.com/resource/pubmed/commentcorrection/18612226-16170134, http://linkedlifedata.com/resource/pubmed/commentcorrection/18612226-16360209, http://linkedlifedata.com/resource/pubmed/commentcorrection/18612226-16402954, http://linkedlifedata.com/resource/pubmed/commentcorrection/18612226-16458968, http://linkedlifedata.com/resource/pubmed/commentcorrection/18612226-16483659, http://linkedlifedata.com/resource/pubmed/commentcorrection/18612226-16490490, http://linkedlifedata.com/resource/pubmed/commentcorrection/18612226-16603955, http://linkedlifedata.com/resource/pubmed/commentcorrection/18612226-16678520, http://linkedlifedata.com/resource/pubmed/commentcorrection/18612226-16828500, http://linkedlifedata.com/resource/pubmed/commentcorrection/18612226-1693009, http://linkedlifedata.com/resource/pubmed/commentcorrection/18612226-17061220, http://linkedlifedata.com/resource/pubmed/commentcorrection/18612226-17101112, http://linkedlifedata.com/resource/pubmed/commentcorrection/18612226-7542796, http://linkedlifedata.com/resource/pubmed/commentcorrection/18612226-9109756, http://linkedlifedata.com/resource/pubmed/commentcorrection/18612226-9709746
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/8804513
pubmed:citationSubset	IM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Angiogenesis Inhibitors, http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal, http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal, Humanized, http://linkedlifedata.com/resource/pubmed/chemical/Coloring Agents, http://linkedlifedata.com/resource/pubmed/chemical/Indocyanine Green, http://linkedlifedata.com/resource/pubmed/chemical/Vascular Endothelial Growth Factor A, http://linkedlifedata.com/resource/pubmed/chemical/bevacizumab
pubmed:status	MEDLINE
pubmed:month	Jun
pubmed:issn	1011-8942
pubmed:author	pubmed-author:ChungHyewonH, pubmed-author:JoeSoo GeunSG, pubmed-author:KimJune GoneJG, pubmed-author:LeeSun YoungSY, pubmed-author:YoonYoung HeeYH
pubmed:issnType	Print
pubmed:volume	22
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	92-9
pubmed:dateRevised	2011-11-17
pubmed:meshHeading	pubmed-meshheading:18612226-Aged, pubmed-meshheading:18612226-Aged, 80 and over, pubmed-meshheading:18612226-Angiogenesis Inhibitors, pubmed-meshheading:18612226-Antibodies, Monoclonal, pubmed-meshheading:18612226-Antibodies, Monoclonal, Humanized, pubmed-meshheading:18612226-Choroid, pubmed-meshheading:18612226-Coloring Agents, pubmed-meshheading:18612226-Combined Modality Therapy, pubmed-meshheading:18612226-Female, pubmed-meshheading:18612226-Fluorescein Angiography, pubmed-meshheading:18612226-Humans, pubmed-meshheading:18612226-Indocyanine Green, pubmed-meshheading:18612226-Injections, pubmed-meshheading:18612226-Male, pubmed-meshheading:18612226-Middle Aged, pubmed-meshheading:18612226-Peripheral Vascular Diseases, pubmed-meshheading:18612226-Photochemotherapy, pubmed-meshheading:18612226-Pilot Projects, pubmed-meshheading:18612226-Retrospective Studies, pubmed-meshheading:18612226-Tomography, Optical Coherence, pubmed-meshheading:18612226-Treatment Outcome, pubmed-meshheading:18612226-Vascular Endothelial Growth Factor A, pubmed-meshheading:18612226-Visual Acuity, pubmed-meshheading:18612226-Vitreous Body
pubmed:year	2008
pubmed:articleTitle	The therapeutic effects of bevacizumab in patients with polypoidal choroidal vasculopathy.
pubmed:affiliation	Department of Ophthalmology, Asan Medical Center, University of Ulsan, College of Medicine, Seoul, Korea.
pubmed:publicationType	Journal Article, Case Reports, Research Support, Non-U.S. Gov't